Santen halts treasury share disposal for remuneration plan

Santen Pharmaceutical Co., Ltd. announced on September 18, 2025, that it has suspended the disposal of treasury shares for its Post-delivery Type Performance-linked Stock Remuneration Plan. This decision was made after the aggregate value of the planned share disposal, initially resolved by the board of directors on September 3, 2025, exceeded 100 million yen. Consequently, Santen requested the withdrawal of its previously submitted Written Notice of Securities to the Kinki Local Finance Bureau on the same day.

The disposal, originally scheduled for September 30, 2025, involved 57,909 shares of the company's common stock at a price of 1,600.5 yen per share, totaling 92,683,353 yen. The shares were to be allocated among two directors (excluding outside directors), four corporate officers, and two leavers.

Santen stated that further details regarding the plan would be announced after its board of directors finalizes their decisions. The company's commitment to eye health remains unchanged as it navigates this adjustment to its remuneration scheme.